The Influence of Androgen Deprivation Therapy on Prostate Size and Voiding Symptoms in Prostate Cancer Patients in Korea.
- Author:
Hoon CHOI
1
;
Hong CHUNG
;
Jae Young PARK
;
Jeong Gu LEE
;
Jae Hyun BAE
Author Information
- Publication Type:Original Article
- Keywords: Androgen Deprivation Therapy; Prostate Neoplasms; Prostate Volume
- MeSH: Follow-Up Studies; Humans; Korea*; Lower Urinary Tract Symptoms; Prostate*; Prostatic Neoplasms*; Retrospective Studies; Urodynamics
- From:International Neurourology Journal 2016;20(4):342-348
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The goal of this study is to investigate the effects of androgen deprivation therapy (ADT) on total prostate volume and lower urinary tract symptoms (LUTS). METHODS: Between January 2007 and June 2014, 110 patients who received androgen deprivation treatment were enrolled in this retrospective study. Clinical parameters and urodynamic parameters along with changes at follow-up were analyzed. Factors such as reduction in prostate volume, changes in LUTS, and prostate volume tertiles were compared 1 year after ADT. RESULTS: After ADT, the total International Prostate Symptom Score (IPSS) score decreased from 17.45 to 12.21 and the IPSS voiding subscore decreased from 9.16 to 6.24. Maximal uroflow rate increased from 8.62 to 11.50 mL/sec and residual urine also reduced significantly by 29.34 mL. Change in prostate size was more prominent (–51.14%) in the patients with less than 1 year of ADT (n=21) than those who had more than 1 year of treatment (n=89, –44.12%). The decrease in the IPSS voiding subscore was greater within 1 year of ADT than after 1 year of treatment (–4.10 vs. –2.65). The differences were more significant in the 30–50 g group (n=59) and >50 g group (n=11) than the <30 g group (n=40) of the IPSS voiding subscore improvement (–3.76 , –4.91 vs. –2.10), and maximal uroflow rate improvement (2.78, 2.90 vs 1.49). CONCLUSION: ADT resulted in statistically significant clinical improvement in terms of prostate volume, urodynamic parameters, and LUTS for patients with prostate cancer when analyzed by ADT duration and prostate volume.
